Overview

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-12-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants

Phase:

PHASE3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

zilucoplan